TOMA BIOSCIENCES Revenue and Competitors

Cancer is not an anatomical disease; it is fundamentally a disease of the genome within cancer cells. TOMA technology enables laboratories to uncover the DNA alterations in cancer cells to provide meaningful data for researchers and clinicians seeking the optimal treatment options for their patients. In a recent study (http://meetinglibrary.asco.org/content/152750-156) conducted by Intermountain Healthcare using TOMA reagent kits, cancer genomic testing nearly doubled the progression free survival of patients with advanced cancer. TOMA OS-Seqâ„¢ technology enables comprehensive analysis of every alteration type from all types of clinical tumor samples. Our reagents and methods amplify only the targets of interest instead of the whole genome, significantly speeding up the library preparation to less than 8 hours. TOMA kits can also be run on your current NGS platform. We offer a fast, simple and efficient way to generate reliable and clinically meaningful sequencing data. For more information, please contact us today. (www.tomabio.com)